Oncology

New research clarifies the definition of "cure" in stage II and III colon cancer, highlighting a six-year milestone for patient reassurance and care efficiency.

The Chinorec trial reveals that combining Yervoy and Opdivo with chemoradiotherapy is safe for rectal cancer, though response rates remain unchanged.

Expedited regulatory paths transform colorectal cancer treatment, enhancing access but creating challenges in clinical evidence and payer decisions.

A groundbreaking NLP algorithm accurately identifies precancerous gastric and esophageal conditions from EHRs, enhancing early detection and personalized patient care.

New research uncovers how cancer-induced nerve injury drives resistance to anti-PD-1 therapy, revealing potential strategies to enhance treatment efficacy.

A new prognostic tool combines albumin-prealbumin-globulin ratio and mid-arm circumference to enhance gastric cancer risk stratification and improve patient outcomes.

The Destinex assay revolutionizes gastric cancer detection with high accuracy, offering a noninvasive, cost-effective liquid biopsy for early diagnosis.

Researchers reveal ELI-002 2P cancer vaccine shows promise in boosting immune responses for colorectal and pancreatic cancer patients, enhancing survival rates.

New research highlights the potential risks of skipping nasogastric tubes after esophageal surgery, suggesting they may reduce anastomotic leak rates.

According to the American Cancer Society, about 22,000 new esophageal cancer cases were diagnosed in 2025 in the U.S., and over 16,000 deaths were attributed to the disease. Risk factors for this carcinoma include obesity, gastroesophageal reflux disease (GERD) and Barrett’s esophagus.

Colorectal cancer screening rates in young adults rise with effective outreach strategies, highlighting the importance of FIT kits for early detection.

H. pylori infection significantly contributes to stomach cancer risk, but effective screening and treatment can prevent millions of cases globally.

Private equity acquisitions have increased rapidly across all aspects of healthcare, with gastroenterology practices experiencing the highest share. In the U.S., approximately 13% of gastroenterologists work in practices owned by private equity groups.

According to the latest edition of The Cancer Atlas, lower-income nations are experiencing a rise in lung, colorectal and breast cancer incidence due to increasing adoption of behaviors associated with economic development—such as tobacco use, poor nutrition and physical inactivity.

Researchers found that altering key enzymes involved in redox balance could disrupt the metabolism of Myc-driven lymphomas, which offers a potential new strategy to treat aggressive cancers.

Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop working, and many patients relapse.

Financial toxicity can affect patient outcomes and quality of life. For example, a patient may forgo treatment or medications to save money, or they may incur high medical debt or go into bankruptcy to pay for medical care.

A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Oncologists should ask in advance about what young patients and their parents want to be told about changing prognoses, a new qualitative study finds

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

One particular application of AI on the rise at City of Hope is the development of a large language model (LLM) made specifically for oncology.